http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HU-9901016-A2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-233 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D521-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 1996-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bee9ee71046450d70c9cc4c018a90271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3787c1350a790320953c67aa56b56d08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f379f4a3cb8efc64e61b82c44d2f8ae0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e320a17588cb5038423410246252068 |
| publicationDate | 2000-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | HU-9901016-A2 |
| titleOfInvention | 4-Quinolinecarboxamide derivatives, their preparation and use as neurokinin-3 (NK-3) and neurokinin-2 (NK-2) receptor antagonists |
| abstract | The present invention relates to a compound of general formula (I): wherein Ar is optionally substituted aryl, cycloalkadienyl or cyclic, aromatic, heterocyclic, aromatic, heterocyclic or cyclenic ring; R is alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted phenyl or phenyl (C 1 -C 6) alkyl, optionally substituted, containing up to four heteroatoms selected from the group consisting of oxygen and / or nitrogen; alkyl, amino-alkyl, alkyl-amino-alkyl, dialkyl-amino-alkyl, acyl-amino-alkyl, alkoxy-alkyl, alkyl-carbonyl, carboxy, alkoxy-carbonyl, alkoxy-carbonyl -alkyl, carbamoyl-alkylaminocarbonyl, dialkylaminocarbonyl, haloalkyl, or a - (CH2) p- ring forming a ring with one of the carbon atoms of Ar, wherein p is 2 or 3; R1 is hydrogen or optionally up to four substituents selected from the group consisting of alkyl, alkenyl, aryl, alkoxy, hydrohexyl, halogen, nitro, cyano, carboxy, carboxy amyl, trifuryl, alkoxy acyl-oxy, phthalimide, amino, synthetic or dialkylamino; R2 is hydrogen, alkyl, hydroxy, halogen, cyano, amino, amino or dialkylamino, alkylsulfonylamino, amino or dialkanoylamino, of which any alkyl moiety is amino or dialkyl; amino-tetanus substituted or -X- (CH2) nY of the general formula; R3 is alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted aryl, cyclic or aromatic, cyclic aromatic heterocyclic; and R4 is hydrogen or alkyl piperidine - either on the monounsaturated salt or on the compound. The compounds of the present invention are NK-3 and NK-2 receptor antagonists. ŕ |
| priorityDate | 1995-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 242.